# Gilead Announces Positive Phase 2 Results for GS-967

**URL:** https://forum.livingwithpsc.org/t/gilead-announces-positive-phase-2-results-for-gs-967/2820
**Category:** Life with Primary Sclerosing Cholangitis
**Created:** [November 9, 2018, 3:25pm UTC](https://forum.livingwithpsc.org/t/gilead-announces-positive-phase-2-results-for-gs-967/2820 "2018-11-09T15:25:42Z")
**Posts on this page:** 1
**Page:** 1

<div class="post-metadata">

### Author: ![Ted](https://sea1.discourse-cdn.com/flex019/user_avatar/forum.livingwithpsc.org/ted/32/381_2.png) [@Ted](https://forum.livingwithpsc.org/u/Ted)
#### Post date: [November 9, 2018, 3:25pm UTC](https://forum.livingwithpsc.org/t/gilead-announces-positive-phase-2-results-for-gs-967/2820/1 "2018-11-09T15:25:43Z")

</div>

SAN FRANCISCO–(BUSINESS WIRE)–Nov. 9, 2018-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC). Data were presented at The Liver Meeting® 2018 in San Francisco.

[https://www.gilead.com/news/press-releases/2018/11/gilead-announces-positive-phase-2-results-for-gs9674-in-primary-sclerosing-cholangitis-psc-at-the-liver-meeting-2018](https://www.gilead.com/news/press-releases/2018/11/gilead-announces-positive-phase-2-results-for-gs9674-in-primary-sclerosing-cholangitis-psc-at-the-liver-meeting-2018)